R&D Merged Scheme Vs ERIS , Decision Tree For £150k Spend
R&D Merged Scheme vs ERIS: Decision Tree for £150k Spend in the UK
For a company spending £150,000 on qualifying R&D in 2026/27, the choice between the merged RDEC scheme and the Enhanced R&D Intensive Support scheme can produce outcomes ranging from £22,500 to over £40,000. The right answer depends on five sequential questions about the company's size, profitability, expenditure mix, and payroll. Getting the wrong answer means leaving a material amount of cash on the table.
The Two Schemes Side by Side
Since 1 April 2024, all UK companies making R&D claims fall into one of two regimes. The merged RDEC scheme applies to the vast majority, including most SMEs. It provides a 20% above-the-line credit on qualifying expenditure, which after corporation tax produces a net benefit of approximately 15% for a profitable company at the 25% main rate, or 16.2% at the 19% small profits rate.
ERIS, the Enhanced R&D Intensive Support scheme, applies exclusively to loss-making SMEs where qualifying R&D expenditure represents at least 30% of the company's total relevant expenditure for the period. The ERIS mechanism produces a payable credit equivalent to approximately 27% of qualifying spend, calculated as 14.5% applied to a 186% enhanced deduction. That credit is cash in hand, not contingent on future profitability.
Neither scheme is available by election. Eligibility is determined by the facts. The question is not which scheme the company would prefer but which scheme the company actually qualifies for.
Decision Point One: Is the Company an SME?
An SME for R&D purposes is a company with fewer than 500 employees and either annual turnover below €100 million or a balance sheet total below €86 million. These thresholds are applied at the group level, aggregating the figures of connected and partner enterprises.
A company that falls outside the SME definition has no access to ERIS regardless of its R&D intensity or loss-making position. It uses the merged RDEC scheme. At £150,000 of qualifying spend, the merged RDEC generates a credit of £30,000, and for a profitable company at the 25% main rate, the net benefit after CT on the credit is £22,500.
If the company is a large company, the decision tree ends here. Merged RDEC, £22,500 net on £150k spend.
For SMEs, the analysis continues.
What this Widget is About: This interactive decision tree widget, created by Atlas Tax Advisors, guides UK business owners and financial directors through the post-April 2024 tax relief rules to identify whether their £150,000 qualifying R&D spend falls under the standard Merged RDEC Scheme or the more lucrative Enhanced R&D Intensive Support (ERIS). By answering a brief series of sequential questions regarding your company size, trading profitability, total operating expenditure, and payroll liabilities, you can immediately determine your statutory scheme eligibility and projected net cash benefit—ranging from £22,500 to over £40,000. To use the tool, simply work through each interactive step or switch to the full flowchart matrix view to visualise how critical statutory tests, including the 30% intensity threshold and PAYE/NIC caps, affect your claim.
Decision Point Two: Is the Company Loss-Making?
ERIS is only available to a company that is loss-making for corporation tax purposes in the relevant accounting period. The test is applied on a tax-adjusted basis before the R&D enhanced deduction itself is applied. A company that would be profitable without the R&D deduction but enters loss once the deduction is applied does not satisfy the condition.
A profitable SME uses the merged RDEC scheme. At £150,000 of qualifying spend and a 25% CT rate, the outcome is the same as for a large company: £22,500 net benefit. For a company at the 19% small profits rate, the credit of £30,000 is offset by CT of £5,700 on that credit income, giving £24,300, approximately 16.2% of qualifying spend.
If the company is profitable, the decision tree ends here. Merged RDEC applies, with a net benefit between £22,500 and £24,300 depending on the applicable CT rate.
For loss-making SMEs, the analysis continues.
Decision Point Three: Does the 30% Intensity Test Work at £150k?
This is where the decision tree produces its most practically important output. ERIS requires that qualifying R&D expenditure represents at least 30% of total relevant expenditure for the period. Total relevant expenditure is broadly the company's operating costs, excluding capital gains, investment income, and CT payments.
At £150,000 of qualifying R&D spend, the intensity test is met only if total relevant expenditure does not exceed £500,000. Put differently: £150k is 30% of £500k. A company spending £150k on R&D and £450k on everything else sits exactly at the 30% boundary. A company spending £150k on R&D but £600k on total costs has an intensity ratio of 25% and does not qualify for ERIS.
This is not an abstract mathematical point. A loss-making software development business with a lean cost base of £350,000 in total (of which £150,000 is qualifying R&D) has an intensity ratio of approximately 43%. ERIS applies comfortably. The same business that has taken on an additional £300,000 of office costs or expanded into a non-R&D product line may now sit below 30%. Intensity is calculated period by period, and a company whose expenditure profile changes materially from one year to the next may move in and out of ERIS eligibility.
The grace period matters here. A loss-making SME that met the 30% intensity condition in its immediately preceding accounting period can still claim ERIS in the current period even if intensity has dropped below 30% in the current year. This one-year grace prevents a single anomalous period, perhaps one with unexpectedly high non-R&D costs, from excluding an otherwise qualifying company from the higher credit rate.
If the intensity test is not met (and the grace period does not apply), the loss-making SME uses merged RDEC. For a loss-making SME that meets the 30% intensity test: ERIS applies, and the analysis moves to the PAYE cap.
The Numbers: What Each Scheme Actually Generates on £150k
At £150,000 of qualifying R&D expenditure, the two outcomes diverge sharply.
Under merged RDEC for a loss-making company: the credit is 20% of £150,000, giving £30,000. The payable amount is then reduced by the corporation tax that would have been due on that credit income, at the applicable rate. For a company in the main CT rate band (25% on profits above £250,000), the payable credit is £30,000 × (1 - 25%) = £22,500, representing 15% of qualifying spend. For a company in the small profits rate band (19% on profits at or below £50,000), the payable credit is £30,000 × (1 - 19%) = £24,300.
Under ERIS for a loss-making SME with sufficient intensity: the enhanced deduction is 186% of £150,000, producing an enhanced loss figure of £279,000 attributable to the R&D. The payable credit is 14.5% of that £279,000, which comes to £40,455. This represents approximately 26.97% of the original £150,000 qualifying spend, conventionally described as 27%.
The difference between the two outcomes: £40,455 under ERIS against £22,500 under merged RDEC. That gap of approximately £18,000 on a single period's claim is the financial incentive to meet and maintain ERIS eligibility.
The PAYE Cap: Where ERIS Can Disappoint
The ERIS payable credit is not automatically £40,455. The cap limits it to three times the company's total PAYE and National Insurance liabilities for the period, plus £20,000.
For a company with PAYE and NIC of £40,000: the cap is (3 × £40,000) + £20,000 = £140,000. The £40,455 credit is well within the cap. Full benefit received.
For a company with PAYE and NIC of £10,000: the cap is (3 × £10,000) + £20,000 = £50,000. Still within cap. Full benefit received.
For a company with PAYE and NIC of £3,000: the cap is (3 × £3,000) + £20,000 = £29,000. This is above the £22,500 that merged RDEC would give, but below the uncapped ERIS figure of £40,455. In this scenario, ERIS still delivers more than merged RDEC: £29,000 versus £22,500. The PAYE cap reduces the benefit but does not eliminate the ERIS advantage.
The cross-over point where capped ERIS exactly equals merged RDEC's payable amount of £22,500 occurs when: (3 × PAYE/NIC) + £20,000 = £22,500, giving PAYE/NIC of £833 per year. In other words, unless a company's entire PAYE and NIC bill for the year is below £833, ERIS generates more than merged RDEC even after the cap applies.
The only scenario where a loss-making ERIS-eligible company would actually receive less from ERIS than from merged RDEC is where PAYE and NIC for the period is zero and the company relies entirely on the £20,000 floor amount. £20,000 versus £22,500 means merged RDEC would have produced a higher payable credit.
In practice, any company with employees paying salaries above the NIC threshold will have a PAYE/NIC bill that puts the cap comfortably above £22,500. The PAYE cap is a genuine constraint for founder-led companies where the director draws dividends rather than salary and has minimal payroll on PAYE. For those companies specifically, confirming whether PAYE/NIC exceeds £833 annually, which is a vanishingly low bar, is the only PAYE cap calculation needed.
Profitable Companies: A Note on the Marginal Relief Zone
For profitable SMEs, there is no ERIS, so the merged RDEC is the only route. But within merged RDEC, the effective net benefit varies with the corporation tax rate, and companies in the marginal relief zone (profits between £50,000 and £250,000) deserve specific attention.
In the marginal relief zone, the effective marginal CT rate is 26.5%. A £150,000 R&D claim generating a £30,000 credit reduces taxable profits (or equivalently, reduces the CT offset required). The net CT saving calculation in this zone is slightly different from the simple 25% or 19% rate computations. The full interaction between the RDEC credit and the company's marginal relief calculation can produce an effective net benefit on the credit slightly above the 15% that the 25% rate produces.
What this Widget is About: This interactive decision-tree widget helps UK companies spending £150,000 on qualifying R&D in 2026/27 quickly determine whether the merged RDEC scheme or the Enhanced R&D Intensive Support (ERIS) applies, and what cash benefit they can expect. Simply answer a short sequence of yes/no questions about company size, profitability, R&D intensity and payroll, or enter your own figures into the built-in calculators, and the tool will guide you to the correct outcome with clear pound figures. It highlights the potential difference of around £18,000 between the two schemes and flags important practical points such as the PAYE/NIC cap and the one-year grace period. Use it as a straightforward first step before taking professional advice on your claim.
The Practical Decision Framework
For a company preparing its 2026/27 R&D claim with £150k of qualifying spend, the questions run in the following order.
First: is it a large company? If yes, merged RDEC at £22,500 to £24,300 net.
Second: is it a profitable SME? If yes, merged RDEC at £22,500 to £24,300 net.
Third: is it a loss-making SME? If yes, proceed to the intensity calculation.
Fourth: does £150k represent at least 30% of total relevant expenditure? If the company's total costs are £500,000 or below, the answer is yes (assuming £150k qualifies in full). If total costs are above £500,000, check the exact ratio. If intensity is below 30%, check whether the previous period met the test (grace period applies for one period only).
Fifth: if ERIS applies, calculate the PAYE/NIC cap: (3 × total PAYE/NIC for the year) + £20,000. If the result is above £22,500, ERIS is unambiguously the better outcome. If it is below £22,500, consider whether merged RDEC would have been accessible (in this scenario it would not be, since ERIS applies as the relevant scheme where conditions are met: the choice is not ERIS versus merged RDEC but ERIS at the capped amount versus the loss carry-forward alternative).
Sixth: pre-notification. A first-time ERIS claimant must have filed the claim notification form within six months of the accounting period end. Without that notification, the claim is invalid regardless of the financial outcome.
Key Takeaways
At £150,000 of qualifying R&D spend in 2026/27, the merged scheme generates a net payable credit of £22,500 at the 25% CT rate for loss-making companies, or up to £24,300 at the 19% small profits rate for profitable companies.
ERIS generates a payable credit of approximately £40,455 on the same qualifying spend, subject to the PAYE and NIC cap, which equals (3 × annual PAYE/NIC) + £20,000. ERIS is more valuable than merged RDEC in virtually every scenario where the company has any meaningful payroll.
ERIS is only available to loss-making SMEs where qualifying R&D expenditure represents at least 30% of total relevant expenditure. At £150k of R&D spend, this means total costs must be £500,000 or below.
The grace period allows ERIS to be claimed in a period where intensity falls below 30%, provided the immediately preceding period met the test.
The PAYE cap produces a cross-over where merged RDEC would be marginally better only when total annual PAYE and NIC is below £833, an almost entirely theoretical scenario for any real business.
Pre-notification is mandatory for first-time ERIS or merged RDEC claimants. The notification form must be submitted within six months of the accounting period end. Missing the window invalidates the claim permanently for that period.
FAQs
Q1: How does the £150k R&D spend threshold influence the choice between the merged scheme and ERIS for a growing SME?
Well, it's worth noting that the absolute spend amount like £150k doesn't directly set eligibility, but it plays a big role in the intensity calculation for ERIS. In my experience with clients, a startup in Manchester spending £150k on qualifying R&D while their total expenditure sits at £400k would hit well over the 30% intensity mark if loss-making, tipping them firmly towards ERIS for that higher payable credit. But if their overall costs balloon due to scaling operations, they might dip below the threshold and default to the merged scheme's more modest but still useful above-the-line credit. Always run the numbers early in the year, I've seen businesses miss out by not forecasting this properly.
Q2: What if my company has fluctuating profitability, could switching schemes mid-year make sense for a £150k project?
In practice, the decision locks in based on your position at the end of the accounting period, so mid-year switches aren't straightforward. Consider a tech firm in Edinburgh projecting profits but ending up with a loss after unexpected costs on their £150k R&D outlay. They might qualify for ERIS if intensity holds, but if they turn profitable, the merged scheme applies instead. From advising similar cases, the key pitfall is assuming you'll stay loss-making, build scenarios in your planning to avoid nasty surprises at filing time. HMRC looks at the full picture, not projections.
Q3: For directors taking dividends or high salaries, how does personal tax position interact with company-level merged scheme vs ERIS claims?
This is a common mix-up I see with owner-managers. The company claims the relief, but your personal extraction strategy matters. With the merged scheme, the taxable credit boosts profits, potentially increasing corporation tax before you draw dividends. ERIS, being more cash-focused for intensive loss-makers, can provide a cleaner injection without the same immediate tax hit at company level. Take a Birmingham-based director with £150k R&D spend: opting for ERIS might preserve more cash for reinvestment or personal drawings, but poor planning around National Insurance or dividend tax bands can erode the benefit. It's always about the holistic view.
Q4: Does having multiple projects, some grant-funded, complicate the decision tree for £150k total spend?
Absolutely, and this trips up many. Grants can affect intensity calculations and eligibility nuances, though the merged scheme is generally more flexible post-2024. Imagine a Leeds engineering firm with £150k split across projects, one partly grant-supported: the qualifying portion still counts towards the 30% for ERIS if loss-making. But misallocating could push you under the threshold. In my client work, the practical tip is meticulous project-by-project tracking from day one, it avoids HMRC queries and ensures you pick the optimal route without double-dipping risks.
Q5: What happens if my SME exceeds SME size limits mid-claim with £150k R&D activity, does ERIS remain an option?
This is an edge case I've navigated for several scaling businesses. ERIS is strictly for SMEs meeting the headcount, turnover, or balance sheet tests throughout the period. If growth pushes you over during the year with that £150k spend, you may lose ERIS eligibility and fall to the merged scheme. A software company in Bristol I advised hit this exactly, they had to recalibrate expectations and documentation. The lesson? Monitor size criteria quarterly and have contingency claims ready under the merged rules.
Q6: How do overseas contractors or remote team costs factor into the £150k spend analysis for scheme selection?
Post-merger rules tightened this, which catches people out. Qualifying overseas expenditure has restrictions, particularly for subcontracted work. For a £150k project involving international talent, only certain UK-linked or exempt costs count fully towards intensity and relief. I've seen London clients with distributed teams lose out by not ring-fencing eligible portions properly. The fix is clear contemporaneous records showing why the work qualifies, it can make or break whether ERIS's higher rate beats the merged scheme's steadier credit.
Q7: For self-employed individuals considering incorporation to access these schemes with £150k planned spend, what's the real-world timing advice?
Incorporation opens the door, but timing is everything. A freelancer in Cardiff planning £150k R&D after going limited needs to align the accounting period start with April 2024+ rules. Pre-incorporation costs generally don't qualify, so delaying heavy spend until post-incorporation maximises options. In my experience, rushing incorporation without proper setup leads to lost claims or suboptimal scheme choice. Get the structure right first, it pays dividends, literally.
Q8: What pitfalls arise with intellectual property ownership or licensing when deciding between schemes for substantial R&D budgets?
IP issues can quietly undermine claims. Under both schemes, you generally need to own or have rights to the IP arising, but ERIS (with its SME heritage) has stricter vibes in some interpretations. For a £150k medtech project, licensing arrangements might dilute eligibility if not structured cleanly. I've advised clients who nearly lost relief due to vague agreements, a simple review upfront avoids this. It’s one of those areas where professional input on contracts saves far more than it costs.
Q9: If cash flow is tight despite £150k R&D investment, how quickly can relief come through under each scheme?
The merged scheme often provides a more predictable above-the-line boost that can help with financing and reporting to investors sooner. ERIS shines for pure cash refunds in loss-making intensive scenarios but can involve longer processing if HMRC scrutinises intensity. From handling urgent cases in the North West, companies that submit robust, well-documented claims see faster payouts. Tip: Engage early with your accountant to prepare the Additional Information form meticulously, it smooths everything.
Q10: How should businesses review past claims or plan future ones when circumstances change around the £150k mark?
Regular health checks are essential as rules evolve. A business hovering near the intensity threshold with £150k spend should model both schemes annually, especially with growth or market shifts. I've recommended to clients in similar positions to maintain a rolling decision log, it highlights trends like increasing intensity that favour ERIS long-term. The biggest value comes from treating this as strategic planning, not just compliance, turning tax relief into a genuine competitive edge. Always double-check your specific facts, as every situation has its nuances.
Disclaimer
The article content is checked against primary sources, including GOV.UK and HMRC guidance and manuals, and is reviewed at least annually. Worked examples and figures are illustrative and are included to show how the rules apply in principle. They are not a calculation of your own liability.
Tax is highly fact-sensitive. Small differences in circumstances, timing, residence, or structure can change the outcome significantly, and the rules themselves change frequently. This article is therefore general information and is not advice for your situation. You should not act, or refrain from acting, on the basis of this article alone. Atlas Tax Advisors accepts no liability for any loss arising from reliance on it without taking advice. For your specific situation, please contact us or any professional accountant.
Comments